Heredodegenerative Disorders, Nervous System: Clinical Trials

2,493 trials for Heredodegenerative Disorders, Nervous System, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1199 completed, 421 recruiting, 277 unknown, 185 terminated. 658 Phase 2, 524 Not applicable, 375 Phase 1, 281 Phase 3, 61 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2658Completed 349, Recruiting 73, Terminated 72, Active not recruiting 60, Unknown 38, Not yet recruiting 32, Withdrawn 23, Enrolling by invitation 8, Suspended 3
Not applicable524Completed 255, Unknown 96, Recruiting 85, Active not recruiting 26, Not yet recruiting 24, Withdrawn 15, Terminated 14, Enrolling by invitation 8, Suspended 1
Phase 1375Completed 192, Recruiting 52, Active not recruiting 40, Terminated 37, Unknown 20, Not yet recruiting 15, Withdrawn 12, Enrolling by invitation 5, Suspended 2
Phase 3281Completed 142, Terminated 40, Active not recruiting 36, Recruiting 23, Unknown 18, Not yet recruiting 8, Withdrawn 8, Enrolling by invitation 6
Phase 461Completed 37, Unknown 9, Recruiting 6, Terminated 5, Active not recruiting 3, Withdrawn 1
Early Phase 131Completed 17, Terminated 5, Recruiting 4, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1

Follow Heredodegenerative Disorders, Nervous System: new trials by email Literature Review of Heredodegenerative Disorders, Nervous System trials Research Report on Heredodegenerative Disorders, Nervous System

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Phase 2 / Phase 3Not yet recruitingFenix Innovation Group402027-07-012026-09-09
IT and IV Lentiviral Gene Therapy for X-ALD
Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
Plasma Pyrophosphate Imbalance According to Phenotype and Bone Remodelling Alterations in Type 1 Neurofibromatosis - PIRATE-NF1 -
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (NFP)
Not yet recruitingUniversity Hospital, Angers402027-04-092026-11-18
Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A
scAAV1.tMCK.NTF3 - Charcot-Marie-Tooth Neuropathy Type 1A
Phase 1 / Phase 2WithdrawnNationwide Children's Hospital2027-04-012026-07-29
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
Huntington Disease
Not yet recruitingBioSensics752027-01-312026-10-13
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome
S247240 Low dose, S247240 Middle dose, S247240 High dose - Fragile X Syndrome (FXS)
Phase 2Not yet recruitingInstitut de Recherches Internationales Servier (I.R.I.S.)1002027-01-252026-11-12
Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)
GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling) - Neurofibromatosis 1 (NF1), Neurofibromatosis Type I
Not applicableSuspendedMassachusetts General Hospital102027-01-012026-06-04
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1)
Phase 2Not yet recruitingUniversity of Alabama at Birmingham552027-01-012026-10-05
SPX-01 Gene Therapy in Pediatric Patients With Spinal Muscular Atrophy Type 1 (RISE)
SPX-01 - Spinal Muscular Atrophy (SMA)
Early Phase 1Not yet recruitingExir Gene Pharmed12027-01-012026-10-29
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor)
Phase 2Not yet recruitingGirish Dhall, MD252027-01-012026-10-28
An Evaluation of the Usefulness, Quality, and Reliability of YouTube®-Based Exercise Videos
Charcot Marie Tooth Disease (CMT)
Not yet recruitingArtvin Coruh University702027-01-012026-11-18
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
Intravenous infusion, Intrathecal injection, umbilical cord mesenchymal stem cell - Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2
Phase 2Not yet recruitingSclnow Biotechnology Co., Ltd.452026-12-312026-04-23
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Phase 2Not yet recruitingWashington University School of Medicine402026-12-312026-10-28
Multi-Modal Digital Monitoring of Disease Symptoms in Spinocerebellar Ataxia
Spinocerebellar Ataxia (SCA)
Not yet recruitingBioSensics252026-12-152026-10-01
Calcium Channel Blocker in Myotonic Dystrophy Type 1
Amlodipine - Myotonic Dystrophy 1
Phase 1Not yet recruitingUniversity of Rochester202026-12-072026-11-09
Muscle MRI Fat Fraction Before Surgery to Predict Strength Recovery After Foot-Drop Surgery in Charcot-Marie-Tooth Disease
Tibialis posterior tendon transfer, Individualized adjunct procedures for cavovarus deformity correction, Ankle-foot orthosis (AFO) - Foot Drop, Charcot-Marie-Tooth Disease Type 1A
Not yet recruitingPeking University Third Hospital1002026-12-012026-10-26
Brain Iron in Beta-Propeller Protein Associated Neurodegeneration (BPAN)
Standardized brain MRI including specific sequences usable for Quantitative Susceptibility Mapping (QSM) - Neurodegeneration With Brain Iron Accumulation (NBIA), Iron Metabolism Disorders
Not applicableNot yet recruitingUniversity Hospital, Bordeaux32026-12-012026-10-09
A Study to Investigate the Effects and Safety of Codabakalner for the Treatment of FXS in Male Participants and Adult Participants With ADS
Codabakalner, Placebo - Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD)
Phase 2 / Phase 3Not yet recruitingSpinogenix1202026-12-012026-10-09
Selumetinib for NF2-Related Schwannomatosis
Selumetinib - Neurofibromatosis Type 2, NF2
Phase 2Not yet recruitingBeijing Tiantan Hospital202026-12-012026-10-28
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
SRX246, Placebo - Aggressive Behavior in Fragile X Syndome
Phase 2Not yet recruitingAzevan Pharmaceuticals802026-12-012026-10-30

Showing 20 of 2493. Sign in to see all of them.

Narrower conditions

Huntington Disease (292)  ·  Tourette Syndrome (234)  ·  Amyloid Neuropathies, Familial (186)  ·  Hereditary Sensory and Autonomic Neuropathies (175)  ·  Neurofibromatosis 1 (175)  ·  Myotonic Dystrophy (126)  ·  Fragile X Syndrome (115)  ·  Charcot-Marie-Tooth Disease (114)  ·  Tuberous Sclerosis (114)  ·  Friedreich Ataxia (111)  ·  Rett Syndrome (95)  ·  Spinocerebellar Ataxias (93)  ·  Hepatolenticular Degeneration (79)  ·  Mucopolysaccharidosis II (77)  ·  Tic Disorders (76)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2489)  ·  Nervous System Diseases (2450)  ·  Genetic Diseases, Inborn (2440)  ·  Neurodegenerative Diseases (2112)  ·  Central Nervous System Diseases (1217)  ·  Brain Diseases (1078)  ·  Neuromuscular Diseases (958)  ·  Nutritional and Metabolic Diseases (750)  ·  Metabolic Diseases (728)  ·  Neurologic Manifestations (717)  ·  Peripheral Nervous System Diseases (714)  ·  Mental Disorders (639)  ·  Congenital Abnormalities (626)  ·  Basal Ganglia Diseases (625)

Interventions

Everolimus (28)  ·  Sirolimus (24)  ·  AZD 6244 (22)  ·  Blood Specimen Collection (20)  ·  Exercise (14)  ·  idursulfase (14)  ·  idebenone (13)  ·  Transcranial Magnetic Stimulation (12)  ·  Aripiprazole (11)  ·  Cannabidiol (11)  ·  Deep Brain Stimulation (11)  ·  alpha-tocotrienol quinone (11)  ·  latrepirdine (11)  ·  pembrolizumab (11)  ·  valbenazine (11)

Sponsors

Assistance Publique - Hôpitaux de Paris (49)  ·  Massachusetts General Hospital (42)  ·  Novartis Pharmaceuticals (41)  ·  National Cancer Institute (NCI) (37)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (31)  ·  Pfizer (29)  ·  NYU Langone Health (26)  ·  AstraZeneca (24)  ·  Children's Hospital Medical Center, Cincinnati (23)  ·  Johns Hopkins University (21)  ·  Institut National de la Santé Et de la Recherche Médicale, France (20)  ·  Shire (17)  ·  University of Florida (17)  ·  University of Rochester (17)  ·  University of Alabama at Birmingham (15)

Countries

United States (1274)  ·  France (373)  ·  United Kingdom (277)  ·  Germany (256)  ·  Italy (250)  ·  Canada (232)  ·  Spain (211)  ·  China (145)  ·  Australia (141)  ·  Netherlands (126)  ·  Belgium (101)  ·  Denmark (80)  ·  Poland (75)  ·  Brazil (74)  ·  Japan (64)

Top investigators

Brigitte C Widemann, M.D. (11)  ·  Staci M Peron, Ph.D. (7)  ·  Ana-Maria Vranceanu, PhD (5)  ·  Elizabeth Berry-Kravis, MD, PhD (5)  ·  Eva Kohegyi, MD (5)  ·  Horacio Kaufmann, MD (5)  ·  Joanne Kurtzberg, MD (5)

Results publications

PMID 36463457, PMID 37460385, PMID 36449262, PMID 38489195, PMID 29480210, PMID 30936738, PMID 32250312, PMID 34108929, PMID 34383289, PMID 40739200, PMID 25803389, PMID 26554876, PMID 28029918, PMID 29023494, PMID 31381524, PMID 32187457, PMID 33395098, PMID 36811812, PMID 37171121, PMID 37460782, PMID 38363467, PMID 39383458, PMID 42389794, PMID 15683544, PMID 17105749, PMID 17562928, PMID 18473686, PMID 19772971, PMID 20483969, PMID 21586746, PMID 21732836, PMID 21779958, PMID 21996156, PMID 22353803, PMID 22868933, PMID 23035069, PMID 24001701, PMID 24144615, PMID 24327518, PMID 24399845, PMID 24780882, PMID 25071871, PMID 25283752, PMID 25519680, PMID 25568297, PMID 25801175, PMID 25988365, PMID 26606867, PMID 26666500, PMID 26714284

NIH funding

2025 (21), 2023 (20), 2018 (19), 2017 (16), 2015 (12), 2019 (11), 2016 (10), 2014 (9), 2009 (5), 2008 (4), U54NS065712 (4), U10CA180886 (3), U54NS048843 (3), U54NS065768 (3), K23HD109375 (2)